P242 Bone density and testosterone levels in male cystic fibrosis patients. (2nd December 2011)

• Record Type: Journal Article
• Authors: Marson, B; Valsalakumari, C; Speight, L; Platts, J; George, L; Ketchell, R I; Duckers, J
• Is Part Of: Thorax. Volume 66(2011)Supplement 4
• Page Start: A166
• Page End: A166
• Publication Date: 2011-12-02
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2011-201054c.242
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: Cystic Fibrosis (CF) is the commonest inherited life threatening condition in the UK and is a multisystem disease. CF related low bone mineral density (BMD) is defined as a Z score 2 SDs below the age and gender matched mean reference value and has been reported in 13% of CF patients.1 Its aetiology is multifactorial with hypogonadism being a potential factor. CF Trust guidelines 2 suggest BMD should be measured and addressed regularly and testosterone levels measured annually in adult males. Aim: To assess the prevalence of low BMD and testosterone in male CF patients attending the All Wales CF Centre. Methods: Annual review records (2008–2009) of BMD derived from DEXA scans and testosterone levels were reviewed retrospectively. Results: 65 male patients (age 18–51 years) were included of whom 60 had a recorded testosterone and BMD. 12 patients (20%) had CF related low BMD (at hip or lumbar spine) of whom three had a low testosterone (<8.0 nmol/l). 12 (20%) patients had low testosterone levels. Of these twelve, three had low leutinising hormone (LH) and nine normal LH and all had normal levels of follicle stimulating hormone. Discussion: CF related low BMD occurs commonly in men with CF with a quarter of those with low BMD also having low testosterone levels. Low testosterone levels per se also occur frequently in this population and recent CF Trust guidelines2 have suggested an endocrinology opinion should be sought where testosterone is found to be low.